PosterSessionOnline

SOCIETY OF HEMATOLOGIC ONCOLOGY

SOHO 2026

September 9-12, 2026 Houston

N. Poster

Poster title

Applicant name

Status


IBCL-004	Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for Indolent and Mantle Cell Lymphomas: A Systematic Review and Meta Analysis	Adarsh Vardhan Tangella	Received

MM-006	Toxicity Spectrum Recalibration With Daratumumab–Bispecific Combination Therapy in Relapsed/Refractory Multiple Myeloma: A Pooled Comparative Analysis	Adarsh Vardhan Tangella	Received

CLL-009	Application of CRISPR-Cas9 Technology in the Treatment of Chronic Lymphocytic Leukemia with P53 Gene Mutations	Aurelian Udristioiu	Received

ABCL-026	A Manifold-Based Topological Approach for Identifying Stage-Divergent Apoptotic Signatures in DLBCL	Alamin Mustafa	Received

AML-037	Topological Reconstruction of DNA Repair Signatures and Survival Divergence in Acute Myeloid Leukemia	Alamin Mustafa	Received

ABCL-086	Trial in Progress (IGNITE): A Phase 3, Multiregional, Open-Label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide (RTX-TMZ) in Relapsed/Refractory (R/R) Primary Central Nervous System Lymphoma (PCNSL)	Kelly McGinty	Received

AML-087	Nationwide Trends in Acute Myeloid Leukemia Mortality Arising From Philadelphia Chromosome-Negative Myeloproliferative Neoplasms in the United States, 1999–2023	Valerin Arno Encarnacion	Received

AML-096	Real-World Outcomes of Azacitidine and Venetoclax in Newly Diagnosed AML and Related High-Risk Myeloid Neoplasms at a Community Hospital	Ravjot Virdi	Received

MPN-099	Initial results from an ongoing Phase 2 open-label study investigating DISC-3405, a novel anti-TMPRSS6 monoclonal antibody, in participants with polycythemia vera (RESTORE-PV)	Cate Garcia	Received

CT-105	Insurance Status, Neurotoxicity, and Clinical Outcomes After CAR-T Therapy in a Highly Socially Vulnerable Cohort	Zara Orozco	Received

MDS-113	Updated overall survival and long-term transfusion independence from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent−naive patients with lower-risk myelodysplastic syndromes	Ally Bousema	Received

MM-116	AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study	Karun Neupane	Received

CLL-119	Clinical Outcomes and Predictors of Early Inpatient CAR-T Administration Within 48 Hours: A Nationwide Analysis	Fiqe Khan	Received

MPN-120	RALLY-MF: Initial efficacy of a Phase 2 study of selcodebart (DISC-0974), an anti-hemojuvelin antibody, to treat anemia in myelofibrosis	Cate Garcia	Received

MPN-129	Efficacy And Safety Of Ropeginterferon In Myeloproliferative Neoplasms: A Systematic Review And Meta-analysis	Mahmood Aldapt	Received

CT-131	Immune Effector Cell (IEC)-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients With Hematologic Malignancies: A Systematic Review and Meta-Analysis	Motaz Almahmood	Received

AML-138	One-Year Survival with Standard 3+7 Versus FLAG/FLAG-IDA Induction in Newly Diagnosed Acute Myeloid Leukemia: A Real-World Propensity Score–Matched Cohort Study	Abdulrahman Ghaleb	Received

IBCL-141	Golcadomide, a potential, first-in-class, oral CELMoD ± rituximab in the phase 1/2 CC-99282-NHL-001 study: long-term follow-up results of patients with relapsed/refractory follicular lymphoma	jeremy altman	Received

ABCL-142	Golcadomide, a potential, first-in-class, oral CELMoD combined with Pola-R-CHP in frontline aggressive B-cell lymphoma: safety and 12-month efficacy	jeremy altman	Received

ABCL-146	Venous Thromboembolism in Lymphoma: Risk Stratification and Evolving Anticoagulation Strategies	Swapnil Surpur	Received

HL-155	Low-Dose Nivolumab Combined With AVD Chemotherapy for Advanced Hodgkin Lymphoma: Interim Results of a Phase 2 Trial	Mobil Akhmedov	Received

MCL-158	Effect of Time to Treatment Initiation in MCL: a SEER Analysis from 2000-2022	Ruby Arora	Received

MPN-161	Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study	Mary Dawod	Received

ABCL-174	Disseminated Extranodal Diffuse Large B-Cell Lymphoma With Genitourinary and Extensive Osseous Involvement Mimicking Metastatic Solid Malignancy	nahla khalil	Received

MPN-204	Projected Healthcare Resource Use and Budget Impact of Once-Daily Extended-Release vs Twice-Daily Immediate-Release Ruxolitinib in Myelofibrosis	Zoe Sand	Received

MM-207	Slowing Mortality Gains in Multiple Myeloma Despite Novel Therapies: Global and SDIBased Disparities From the GBD 2023 Study (1990–2023)	Tapan Giri	Received

AML-208	Profile and Treatment Outcomes of Filipino Acute Myeloid Leukemia Patients Managed at a Tertiary Institution: A Single-Center, 10-Year Retrospective Study	Roanne Ilano	Received

ABCL-216	Effect of HIV Infection on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma	Anastasia Galitsyna	Received

ALL-221	Healthcare Resource Use and Economic Burden of B-cell Acute Lymphoblastic Leukaemia for Patients in the US	Neil Palmisiano	Received

MM-224	Outcomes and Toxicity of CAR T-Cell Therapy in Patients With Renal Impairment: A Propensity Score-Matched Analysis in Relapsed/Refractory Multiple Myeloma	Anushareddy Muddasani	Received

MM-226	Safety and Effectiveness of Bispecific Antibody Therapy Across the Spectrum of Kidney Function in Relapsed/Refractory Multiple Myeloma	Anushareddy Muddasani	Received

CT-227	Measurable Residual Disease by Circulating Tumor DNA in Patients With Third-Line or Later Relapsed or Refractory Follicular Lymphoma Treated With Lisocabtagene Maraleucel in TRANSCEND FL	Alex Verdeur	Received

CT-228	Outcomes of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: First Real-World Data From the CIBMTR	Alex Verdeur	Received

CT-230	Outcomes of Lisocabtagene Maraleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma: First Real-World Data From the CIBMTR	Alex Verdeur	Received

ABCL-231	A Rare Case of Mediastinal Gray Zone Lymphoma Presenting With Tracheoesophageal Fistula	Ritwik Dey	Received

MPN-237	Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo	Leah Eardley	Received

ABCL-241	Real-World Characteristics, Treatment Patterns, and Outcomes of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated in First-Line in the United States Community Oncology Setting	Helen Latimer	Received

CT-243	Quality of Abstracts in Contemporary Hematology-Oncology Trials: A CONSORT Adherence Analysis of Over 15 Years	Maya Hajeh	Received

MM-251	Distinct Inpatient and Post-Discharge Risk States Defined by AKI and Acute Dialysis in Multiple Myeloma Hospitalizations	Woo Joo Lee	Received

AML-252	Concentration of Hemorrhagic Burden and Interhospital Transfer Vulnerability in Acute Promyelocytic Leukemia: A Nationwide Analysis, 2016–2022	Woo Joo Lee	Received

AML-256	EASIX Score Predicts Severe Acute GVHD and Mortality After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Study	Juliana Faleschini	Received

ABCL-257	Neutrophil-to-Lymphocyte Ratio and SIRI Are Associated with Survival and Relapse in Diffuse Large B-Cell Lymphoma: A Single-Center Study	Juliana Faleschini	Received

MPN-269	Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis From IMbark Versus Real-World Data and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow-Up	Mary Ellyn Zola	Received

MPN-276	MORTALITY TRENDS IN HEMATOLOGIC MALIGNANCIES WITH ALCOHOLIC LIVER DISEASE AND CIRRHOSIS IN THE UNITED STATES, 1999–2024	Muhammad Rafay Rafique	Received

ALL-280	Topological Simplification and Loss of Regulatory Complexity in the DNA Repair Pathway of Acute Lymphoblastic Leukemia	Alamin Mustafa	Received

MM-287	Trends and Disparities in Mortality due to Multiple Myeloma and Malignant Plasma Cell Neoplasms Coexisting with Malignant Neoplasms: A 26-Year CDC Wonder Analysis From 1999 – 2024	Atif Hussain Sarwar	Received

IBCL-290	Light Chain Amyloidosis in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Treatment Strategies and Outcomes of 74 Cases	Nicolò Danesin	Received

AML-292	Weekly Metronomic HMA + Venetoclax in Older Adults with Myeloid Neoplasms: A Real-World Experience	Mahmood Aldapt	Received

IBCL-293	CD10 Loss Defines a Biologically Distinct and Extranodal-Enriched Subset of Follicular Lymphoma: A Systematic Review and Meta-Analysis	Adarsh Vardhan Tangella	Received

IBCL-295	Relapse–Mortality Trade-off Between Autologous and Allogeneic Stem Cell Transplantation in Relapsed Follicular lymphoma and Marginal zone lymphoma: A Registry-Based Proportional Meta-Analysis	Adarsh Vardhan Tangella	Received

MPN-298	Correlation Among IL-8, TNF-a, and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus Kinase Inhibitor (JAKi) in the IMbark Trial	Mary Ellyn Zola	Received

TCL-302	The Role of Frontline Hematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma-Not Otherwise Specified	Firas Baidoun	Received

CML-310	Deep Molecular Response Duration Predicts Treatment-Free Remission In CML Rescued After Resistance, Warning or Major Molecular Response	Delphine Rea	Received

ABCL-313	waveLINE-011: Zilovertamab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP as First-Line Therapy in Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma	Dymond Challenger	Received

MCL-322	Real-world implementation of the TRIANGLE regimen (without ASCT) in newly diagnosed mantle cell lymphoma: A multicenter analysis of effectiveness and safety	Teresa Bedoya Palop	Received

MM-326	New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study	Jennifer Kern-Sliwa	Received

IBCL-334	Fixed Duration Subcutaneous Mosunetuzumab had Better Practice Efficiency versus Treat-to-Progression Subcutaneous Epcoritamab in Third-Line or Later Follicular Lymphoma: An Economic Analysis	Isobel Neill	Received

MM-338	Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study	Jennifer Kern-Sliwa	Received

CT-341	Real-World Treatment Patterns, Chimeric Antigen Receptor T Cell Therapy Referral Barriers, and Time-to-Next Treatment in Patients With Third-Line or Later Follicular Lymphoma Who Experienced Progression ≤ 24 Months of First-Line Chemoimmunotherapy: a United States Claims Analysis	Alex Verdeur	Received

ABCL-346	Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma	Alex Verdeur	Received

AML-384	Venetoclax?in Combination With?a Hypomethylating Agent for Patients With?Newly Diagnosed Acute Myeloid Leukemia Who Are?Medically?Unfit for Intensive Induction Therapy: A Real-World Community Experience	Chiara Perni	Received

MM-390	Population-Level Multiple Myeloma Mortality Trends in the BCMA Era: Age-Specific Racial and Regional Disparities in the United States, 2018–2024 (CDC WONDER Analysis)	Tapan Giri	Received

MDS-392	A crossroad between DDX41 mutant hematologic and solid cancers	Serhan Unlu	Received

TCL-393	Disseminated HSV-2 Infection Presenting As Secondary Hemophagocytic Lymphohistiocytosis With Complete Hematologic Recovery Following Antiviral Therapy	Fatih Kaner	Received

TCL-416	Updated Clinical Data from the Phase 1/2 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients with Relapsed/Refractory Cytotoxic T/NK Cell Lymphomas	Wan-Jen Hong	Received

TCL-418	Updated Clinical Data from the Phase 1 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients with Large Granular Lymphocytic Leukemia	Wan-Jen Hong	Received

CT-422	Cost-effectiveness Analysis of Teclistamab and Daratumumab Versus Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma	Sohaib Irfan	Received

MPN-425	Baseline Predictors of Survival and Spleen Response in Ruxolitinib-Treated Myelofibrosis: Development of the Ruxolitinib Prognostic Scoring System in a Real-World Cohort	Alessandro Laganà	Received

CLL-427	Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton´s tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy	Lee Miller	Received

CLL-429	DAYBreak CLL-201: A Study of Bexobrutideg (NX-5948), a Bruton´s Tyrosine Kinase (BTK) Degrader, in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated with a Covalent BTK Inhibitor, a Non-covalent BTK Inhibitor and a BCL2 Inhibitor	Lee Miller	Received

CLL-432	DAYBreak CLL-306: A Phase 3 Randomized Open-Label Trial of the Novel Bruton´s Tyrosine Kinase (BTK) Degrader Bexobrutideg (NX-5948) Versus Pirtobrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)	Lee Miller	Received

ABCL-438	Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LCBL): Updated efficacy and safety from the Phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups	Isobel Neill	Received

MM-442	An Actionability Score for BCMA-, GPRC5D-, and CD38-targeted therapy selection in multiple myeloma	Hannah Oman	Received

ABCL-443	Cross-disease stratification by genetic classifier Lymphly reveals shared molecular programs across B-cell malignancies	Hannah Oman	Received

CLL-450	Pirtobrutinib versus covalent BTK inhibitors in treatment-naïve CLL: a systematic review and network meta-analysis	Junaid Anwar	Received

MDS-456	Improving Survival and Increasing Disease Burden in Chronic Myelomonocytic Leukemia: Population-Based Trends and Projections from SEER, 2000–2022	Arjun Syal	Received

MM-458	Secondary Primary Malignancies Associated With BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A FAERS Pharmacovigilance Analysis	Carmel Awadallah	Received

MM-467	Identification of RNASEL and ROCK1 as Geometric Bottlenecks in Multiple Myeloma via Discrete Ricci Curvature Analysis	Alamin Mustafa	Received

AML-477	The Efficacy of Pivekimab Sunirine (PVEK) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm With Baseline Skin Involvement in the CADENZA Study	Sarah Tasker	Received

MPN-481	Mutant Calreticulin–Specific Monoclonal Antibody, INCA033989, Is Well Tolerated and Achieves Rapid and Sustained Hematologic and Molecular Responses in Patients With Essential Thrombocythemia	Kristina Cunillera	Received

ABCL-483	Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO	Isobel Neill	Received

ABCL-484	A Real-World Study of the Effectiveness and Safety of Post-Tafasitamab Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)	Catrina Tice	Received

ABCL-489	Primary Outcomes From the Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (frontMIND)	Catrina Tice	Received

IBCL-492	Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses	Larissa Borys	Received

AML-498	Favorable Outcomes Including Post-Transplant Survival Are Seen Independent of Baseline Skin Burden in Treatment-Naïve Patients (Pts) With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Tagraxofusp (TAG): Subgroup Analysis of a Pivotal T	Nancy Chidel	Received

CT-504	LACE-Conditioned Autologous Stem Cell Transplantation in Lymphoma: A Safe and Effective Regimen	Sarah El-Zahab	Received

IBCL-510	Clinical Characteristics and Survival Outcomes in Waldenström Macroglobulinemia: An Updated Analysis of 10574 Patients From the SEER Database (1975–2020)	Alamin Mustafa	Received

ALL-514	Treatment-Emergent Adverse Events Associated With Patient-Reported Treatment Burden in Patients With Ph+ ALL: Results From the Phase 3 PhALLCON Study	Christopher Dieyi	Received

CML-516	Event-free survival and safety with ponatinib in patients with chronic-phase chronic myeloid leukemia: 5-year follow-up of OPTIC	Sean ODonnell	Received

ABCL-517	HIV-Associated Plasmablastic Lymphoma Presenting With Spontaneous Tumor Lysis Syndrome and Hypercalcemia of Malignancy	Ritwik Dey	Received

AML-519	Target Dependence and Trial Design Drive Variable Outcomes With BH3 Mimetics in Hematologic Malignancies	Paul Fletcher	Received

AML-520	Myelodysplasia Related Mutation Clearance Is Associated with Improved Outcomes in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Low-Intensity Therapy (LIT)	Naszrin Arani	Received

MPN-528	Timing of TP53 Mutation Acquisition as a Determinant of Outcomes in Patients with Myeloproliferative Neoplasms and Myeloproliferative Neoplasms/ Myelodysplastic Syndromes	Sharan Jhaveri	Received

CT-531	Outpatient CAR-T Therapy for Relapsed/Refractory Lymphoma: A Single-Center Experience	Aditi Saha	Received

CT-535	Disease Aggressiveness Index: A Novel Pre-Infusion Risk Stratification Tool for Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma	Sohaib Irfan	Received

ABCL-537	Immune Checkpoint Inhibitor–Associated Hemophagocytic Lymphohistiocytosis: A Systematic Review	Motaz Almahmood	Received

CT-544	Immune Effector Cell–associated Hemophagocytic Lymphohistiocytosis–like Syndrome In Patients With Hematologic Malignancies: A Systematic Review And Meta-analysis	Mahmood Aldapt	Received

MPN-545	The conformation-selective PI3Kδ inhibitor roginolisib synergizes with JAK inhibitors in progenitor cells from naïve and JAK inhibitor-refractory/resistant patients with myelofibrosis	Giusy Di Conza	Received

CML-547	Impact of Posterior Reversible Encephalopathy Syndrome on Hospitalization and Mortality in Tyrosine Kinase Inhibitor-Treated Patients with Hematologic Malignancies: A Real-World Propensity-Matched Analysis	Katherin Zambrano	Received

MM-548	Navigating Bispecifics Outpatient step-up dosing: A Roadmap To Help improve SafeTy and Access in the Real-world (NORTHSTAR)	Chloe Henry	Received

IBCL-549	Two-Year Rituximab Maintenance versus Observation after First-Line Bendamustine - Rituximab (B-R) in Waldenström´s Macroglobulinemia	Mathias Rummel	Received

IBCL-552	Administering Tafasitamab, Lenalidomide, and Rituximab for Follicular Lymphoma: A Single Institution Experience From the Phase 3 inMINDStudy	Catrina Tice	Received

MPN-553	Preclinical Evaluation of INCA035784, a Novel T-Cell–Redirecting Antibody for the Treatment of mutCALR-Driven Myeloproliferative Neoplasms (MPNs)	Kristina Cunillera	Received

MPN-554	Mutant Calreticulin–Specific Monoclonal Antibody, INCA033989, Is Well Tolerated and Achieves Robust Spleen, Anemia, and Molecular Responses in Patients With Myelofibrosis	Kristina Cunillera	Received

MPN-556	Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, Produces Clonal Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis	Kristina Cunillera	Received

MPN-558	Healthcare Provider Perspectives on the Phlebotomy Visit Workflow in Polycythemia Vera and Associated Healthcare Resource Utilization in the United States	Pankit J Vachhani	Received

CLL-560	How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real World Evidence from the Targeted Therapy Era	Laura Ramsey	Received

AML-562	Predictors of Long-Term Response to Olutasidenib in Mutant IDH1 Acute Myeloid Leukemia (AML)	Eliza Norrell	Received

MPN-564	Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib	Christopher Jaccoma	Received

ABCL-568	Subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin shows a sustained progression-free survival (PFS) benefit compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) large B-cell lymphoma after long-term follow-up	Isobel Neill	Received

MM-569	Mezigdomide, carfi lzomib, and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma: results from the phase 3 SUCCESSOR-2 trial	Jenny Mark	Received

MPN-572	Real-World Phlebotomy (PHL) Burden and Treatment Gaps in US Patients with Polycythemia Vera (PV)	Andrew Srisuwananukorn	Received

MCL-575	Updated Results From the Phase 3 ECHO Trial of Bendamustine-Rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: 50 Months of Follow-up	Kelly Montenegro	Received

ALL-576	Systematic Literature Review and Network Meta-Analyses of Hypersensitivity in Patients Receiving Asparaginase Treatment	Luke Maese	Received

MM-578	Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible/Deferred (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Updated Results From the CC-220-MM-001 Trial	Jenny Mark	Received

ALL-584	SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY	Paul Fletcher	Received

MPN-586	Mutational Landscape and Hematological Correlations in Myeloproliferative Neoplasms: A 5-Year Retrospective Study from a Lebanese Tertiary Center	Sarah Gerges	Received

ALL-589	Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LBP) or Philadelphia Chromosome–Positive B-Cell Precursor Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)	Paul Fletcher	Received

ALL-597	Updated results of POLARIS-1 (Part 1), a global registrational phase 3 study: olverembatinib combined with low-intensity chemotherapy in newly diagnosed Ph+ ALL	Paul Fletcher	Received

CML-603	Treatment-Free Remission (TFR) for newly diagnosed Accelerated Phase Chronic Myeloid Leukemia (AP-CML)	Fadi Haddad	Received

MM-609	Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study	Sloan Smith	Received

AML-610	Longer Survival With Tagraxofusp (TAG) vs Venetoclax (VEN) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Real-World Analysis	Nancy Chidel	Received

ABCL-615	EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)	Kristina Aguilera	Received

ABCL-619	Epcoritamab + Chemoimmunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results From Arms 4 and 10 of EPCORE NHL-2	Jennifer Pearsall	Received

CLL-620	Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge	Adela Perolla	Received

AML-623	Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101	Anna Sitarski	Received

ABCL-629	A Multicenter, Phase 1 Study of KITE-753 in Patients With Relapsed/Refractory (R/R) B-Cell Lymphoma (BCL): Updated Safety and Efficacy Results	Elena Bernewitz	Received

AML-632	Revumenib Therapy Post-Hematopoietic Stem Cell Transplant for Patients With Relapsed/Refractory KMT2Ar, NPM1m, and NUP98r Acute Myeloid Leukemia: Post Hoc Analysis of Outcomes From AUGMENT-101	Anna Sitarski	Received

MPN-637	Ruxolitinib-Induced Complete Molecular Remission in Polycythemia Vera	Nooshin Beygui	Received

MPN-638	Myelofibrosis with Monocytosis is Clinically and Prognostically Similar to CMML	Patrick Crorkin	Received

MDS-646	Real-world Outcomes of Imetelstat: Interrogating Safety, Efficacy and Predictors of Response in Heavily Pretreated Lower-Risk MDS Patients	Rami Komrokji	Received

MM-647	Primary Prophylaxis with Immunoglobulin Replacement Therapy Is Associated with Lower Cumulative Infection Burden and Healthcare Utilization in Patients with Multiple Myeloma Receiving BCMA-Directed BsAbs	Rahul Rajkumar	Received

CT-660	High Specificity but Limited Sensitivity: Is The Khorana Score Sufficient as a Stand-Alone tool to guide Thromboprophylaxis in Contemporary Oncological Practice	Manpreet Saini	Received

CLL-662	Retreatment With Venetoclax-Based Therapies in Relapsed Chronic Lymphocytic Leukemia: A Pooled Analysis of Outcomes Based on Treatment-Free Intervals and Cytogenetic/Molecular Risks	Jun Chih Wang	Received

HL-671	Primary Bone Marrow Hodgkin Lymphoma in Adults: A Systematic Review of Clinical Features, HIV/EBV Associations, and HLH Overlap	Anthony Navarrete Rios	Received

MPN-672	Venous Thrombotic Outcomes in Pregnant Patients With Myeloproliferative Neoplasms: A Propensity Score-Matched Analysis	Rushi Shah	Received

MPN-674	INVESTIGATIONAL PIM1 INHIBITOR NUVISERTIB IN COMBINATION WITH MOMELOTINIB SHOWED PROMISING CLINICAL ACTIVITY IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: DATA FROM AN ONGOING GLOBAL PHASE 1/2 STUDY	Regina Gayatinea	Received

CT-680	Outcomes of Eculizumab Treatment in Adults with High-Risk Transplant Associated Thrombotic Microangiopathy	Manuel Espinoza Gutarra	Received

CT-681	Remote Monitoring for Early Detection of CRS and ICANS in CAR-T Therapy: A Systematic Review with Geriatric Considerations	Sara Ali	Received

AML-685	Machine Learning for Frailty Stratification in Hematologic Malignancies A Systematic Review of Predictive Models for Treatment Toxicity and Survival	Youmna Ismail	Received

AML-703	Real-World Experience with Revumenib: A Single-Center Analysis of Efficacy and Tolerability	Umar Iqbal	Received

ALL-706	Clinical outcomes in adult patients with relapsed/refractory acute lymphoblastic leukemia (R/R B-ALL) who achieved remission following treatment with obecabtagene autoleucel (obe-cel) in the FELIX study	Sharon Martin	Received

CML-709	Co-Existing Myeloid Mutations at Diagnosis Are Associated With Increased Tyrosine Kinase Inhibitor Utilization in Chronic Phase CML	Umar Iqbal	Received

AML-712	Revumenib plus intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708	Anna Sitarski	Received

MPN-718	Hematocrit control, symptom burden and time toxicity among phlebotomy-treated patients with polycythemia vera in the United States	Lindsay Rein	Received

AML-723	Clinical Activity of Revumenib in Patients With Relapsed/Refractory NUP98-Rearranged Acute Leukemias	Anna Sitarski	Received

TCL-727	A Phase I Study of Mogamulizumab in Combination with Brentuximab Vedotin in Previously Treated Mycosis Fungoides and Sézary Syndrome	Lauren Shea	Received

CML-731	Efficacy of Olverembatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) With Prior Resistance to Ponatinib or Asciminib and ASXL1 Mutations	Paul Fletcher	Received

MPN-733	Hydroxyurea-Driven TP53 homozygosity accelerates Leukemic Transformation in CALR-mutant MPNs	Syrine BEL HAJ YAHIA	Received

ABCL-736	Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study	Isobel Neill	Received

AML-739	Post-Transplant Oral Azacitidine Maintenance: Clinical Outcomes and Immune Landscape	Gabriela Sanchez-Petitto	Received

IBCL-740	Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND	Jennifer Pearsall	Received

MM-744	Nonrelapse Mortality Across Anito-cel and Other BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis	Kristen Hurley	Received

MPN-752	Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naive Myelofibrosis: Phase 3 SENTRY Trial	Dominirose Goodwin	Received

MM-754	Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO and Phase 1b TCD15484 Trials	Sloan Smith	Received

MPN-756	CPX-351 Versus Standard of Care as Bridging to AlloHCT in Patients With Higher-Risk Myelodysplastic Neoplasms or Oligoblastic Acute Myeloid Leukemia: Results of the Randomized Phase 2 PALOMA Study	Uwe Platzbecker	Received

AML-758	Co-Mutational Patterns and Transcriptomic Heterogeneity Within NPM1-Mutated Acute Myeloid Leukemia: An Integrative Analysis Using the ASH HematOmics Program	Wajeeha Aiman	Received

CLL-763	Pirtobrutinib´s cardiac adverse reactions: An Early Pharmacovigilance Study	Maroun Ibrahim	Received

MM-766	Isatuximab-Carfilzomib-Dexamethasone Triplet Therapy: Real-World Data Based on the Hungarian Managed Access Program	Mate Huszar	Received

HL-767	An analytical study of the efficacy and safety of Brentuximab vedotin in Hodgkin lymphoma	Kavya Ammineni	Received

MM-768	Net cost recovery associated with inpatient administration of step-up dosing of bispecific antibodies among Medicare patients with relapsed/refractory multiple myeloma	Simren Gill	Received

MM-770	Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma Responding to Bridging Therapy: CARTITUDE-4 Cytogenetic Subgroup Analysis	Erika Schneider	Received

AML-773	Efficacy of Revumenib in Acute Myeloid Leukemia Harboring NPM1-Mutated Co-Mutations: Post Hoc Analysis of AUGMENT-101	Anna Sitarski	Received

MDS-775	Early Real World Use and Hematologic Outcomes With Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review	Mary Ellyn Zola	Received

AML-776	Treatment Patterns and Outcomes of Ivosidenib in Patients With mIDH1 AML Previously Treated With Venetoclax-Based Regimens: A Real-World Analysis	Lisa Pawlak	Received

ALL-777	The effect of obecabtagene autoleucel(obe-cel) on adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD)	Sharon Martin	Received

ALL-779	Levocarnitine and Vitamin B complex for prophylaxis against pegasparaginase toxicity in adults with acute lymphoblastic Leukemia.	Arunkumar Modi	Received

MM-780	Updated Results From the Phase 2 IZALCO Study: Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients	Wanda Vila-Carriles	Received

AML-781	Immune Cell Type abundance predicts survival of pediatric Acute Myeloid Leukemia Patients at Diagnosis	Jaclyn Shaw	Received

AML-784	Real-World Treatment Patterns and Outcomes With Olutasidenib After Venetoclax in IDH1-Mutated Acute Myeloid Leukemia Using Electronic Health Record Data	Eliza Norrell	Received

AML-792	Treatment Patterns and Outcomes With Olutasidenib After Venetoclax in IDH1-Mutated AML Using Real-World Data From Chart Review	Eliza Norrell	Received

CLL-796	Pirtobrutinib in Treatment-Naïve (TN) Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Pooled Results From BRUIN CLL-313 and BRUIN CLL-314	LAURA L RAMSEY	Received

MM-803	Correlation Between Mobilization Regimen and CD34? Stem Cell Yield in Multiple Myeloma (MM) Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT): A Single-Center Retrospective Analysis	Solomiia Hlukhovska	Received

MPN-809	Characterizing the humanistic burden of anemia associated with myelofibrosis through patient-reported outcomes: findings from a systematic literature review	Adaeze Q. Amaefule	Received

MDS-812	Ofirnoflast (HT-6184), a First-in-Class Allosteric NEK7 Inhibitor, Achieves Durable Transfusion Independence (TI) and Hematological Improvement-Erythroid (HI-E) in ESA-Refractory Lower-Risk Myelodysplastic Syndrome (LR-MDS): Phase 2 Final Results	Devan Bursey	Received

MCL-814	Descriptive Characteristics of NOTCH1-Mutated Mantle Cell Lymphoma	Ayda Soltanian	Received

MDS-819	Hematologic Improvement in Lower-Risk MDS (LR-MDS): Clinical Significance of Platelet and Neutrophil Recovery with Ofirnoflast, a Potent allosteric inhibitor of NEK7/NLRP3 Assembly	Devan Bursey	Received

MDS-824	Elritercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naïve adults with lower-risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia: The ELRiSE MDS phase 3 study	Valeria Santini	Received

MDS-827	Allosteric NEK7 Inhibition with Ofirnoflast (HT-6184) Suppresses Mitochondrial Stress, Reduces Systemic Inflammatory Cytokines, and Attenuates Clonal Expansion in Lower-Risk Myelodysplastic Syndrome	Devan Bursey	Received

AML-829	Comparison of Ivosidenib- and Venetoclax-Based Treatment Sequencing and Outcomes in Patients With mIDH1 AML: A Real-World Study	Lisa Pawlak	Received

MPN-832	Update From the Phase 2 RESTORE Trial of Elritercept in Patients With Myelofibrosis Receiving Ruxolitinib	Ciro Rinaldi	Received

MDS-838	Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms	Rami Komrokji	Received

TCL-839	A Multicenter Open Label Phase 3 Randomized trial of Duvelisib vs Investigators choice (Gemcitabine or Bendamustine) Relapsed/Refractory T Cell Lymphoma with T Follicular Helper Phenotype	Sheila waters	Received

MM-845	The Impact of First-Line Daratumumab on Light-Chain Amyloidosis Survival: A Real-World Analysis of 70 Patients	Fruzsina Szél	Received

ABCL-853	Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/ refractory B cell non-Hodgkin lymphoma: Long-term follow-up results from the ANTLER phase 1 trial	Erik MacLaren	Received

ALL-866	Three-Year Follow-Up of Dose-Dense Mini-CVD in Combination with Inotuzumab Ozogamicin and Blinatumomab for Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	Hannah Goulart	Received

ABCL-869	Rondecabtagene Autoleucel, a Dual-Targeting CD19/CD20 CAR T-Cell Therapy, Exhibits a Manageable Safety Profile with Low Rates of Grade ≥ 3 CRS and ICANS in Relapsed/Refractory Large B-Cell Lymphoma	Jigar Desai	Received

MM-870	Isolated CNS Relapse Despite Systemic CR Following Extramedullary Disease in Primary Plasma Cell Leukemia	Sabaa Saad-Omer	Received

MPN-875	Upfront Pemigatinib for Chronic-Phase Myeloid/Lymphoid Neoplasm with a Novel FGFR1 Rearrangement Presenting as Transient Bilateral Vision Loss: A Case Report	Maria Felix Torres Nolasco	Received

MM-881	REAL-WORLD SAFETY PROFILE OF CILTACABTAGENE AUTOLEUCEL IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA: A TRINETX ANALYSIS	Hira Cheema	Received

CLL-888	Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis	Hira Cheema	Received

MCL-906	Real-World Outcomes of Lisocabtagene Maraleucel in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma	Sally Jones	Received

MPN-908	MODULATION OF HEPCIDIN PATHWAY PRODUCES HOMOGENOUS ERYTHROPOIETIC SUPPRESSION BUT HETEROGENOUS IRON REPLETION IN POLYCYTHEMIA VERA: LESSONS FROM REVIVE AND IMPRSSION.	Ashiya Loomba	Received

ABCL-910	Ribosomal Stoichiometric Reprogramming and Integrated Stress Response Activation Define a Translational Stalling State in DLBCL Non-Responder CAR-T Infusion Products	Ecem Kalemoglu	Received

ALL-912	Outcomes of Ruxolitinib in Adult Patients with Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell Transplantation: A Propensity Score-Matched Real-World Analysis	Ecem Kalemoglu	Received

CML-913	Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes	Ecem Kalemoglu	Received

ABCL-914	Metabolic Autonomy of Cytotoxic Programs Distinguishes Responder from Non-Responder CAR-T Effectors in DLBCL: A Single-Cell Co-Expression Network Analysis	Ecem Kalemoglu	Received

MM-919	IDENTIFICATION OF PREDICTIVE FACTORS FOR SEVERE INFECTION IN MULTIPLE MYELOMA: A RISK MODEL DEVELOPMENT AT TERTIARY CARE CENTER	Maria Fernanda Montes Rodriguez	Received

CML-929	Validation of a Prognostic Score in Blast Phase CML: A Cure CML Consortium Analysis	Akriti Jain	Received

CT-931	Preliminary Safety and Efficacy of Myeloablative Orca-Q in Patients with Haploidentical Donors	Breanne Fishman	Received

MM-937	Comparative Analysis of Subcutaneous Isa VRd (ISASOCUT) and Intravenous Isa VRd (IMROZ) in Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma Across Age Groups	Zachary Lawrence	Received

MPN-944	EFFICACY AND MOLECULAR DYNAMICS OF ROPEGINTERFERON ALFA-2B IN HIGH-RISK ESSENTIAL THROMBOCYTHEMIA: TWO-YEAR RESULTS FROM THE PHASE 3 SURPASS-ET TRIAL	Chanyen Tsai	Received

MM-948	Real-World Utilization and Survival Outcomes of Palliative Radiation Therapy in Multiple Myeloma Patients Receiving BCMA-Targeted Therapies: A Propensity Score-Matched TriNetX Analysis	Wei Ju Lin	Received

MDS-964	Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes	Mohamed Khamis	Received

AML-971	MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis	Sai Mourya Meda	Received

MPN-973	A phase 3, double-blind, randomized trial evaluating the efficacy and safety of elritercept versus placebo in patients with myelofibrosis (MF) and anemia on concurrent ruxolitinib therapy: the ELRISE MF study design	Prithviraj Bose	Received

MPN-985	Effect of rusfertide on cytoreductive therapy use in patients with phlebotomy dependent polycythemia vera: post hoc analysis from the randomized controlled phase 3 VERIFY study	Mary Dawod	Received

HL-988	FROM LYMPHOMA MORTALITY TO SURVIVORSHIP MORTALITY: CHANGING UNDERLYING CAUSES OF DEATH AMONG HODGKIN LYMPHOMA-ASSOCIATED DECEDENTS, 2003–2024	Aroog Khaliq	Received

CT-989	Clinical Outcomes and Safety Profile of CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis	Momna Nisar	Received

AML-1008	Clinicopathological features, co-mutational patterns and outcomes in NPM1-mutated adult acute myeloid leukemia patients treated at Singapore General Hospital	Than Hein	Received

HL-1010	Health-Related Quality of Life of Patients With Advanced-Stage Classic Hodgkin Lymphoma Treated With BrECADD and eBEACOPP: Results From the HD21 Study	Fjoralba Kristo	Received

HL-1012	Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated with BrECADD and eBEACOPP: New Data from the HD21 Trial	Fjoralba Kristo	Received

MCL-1013	Concurrent High-Risk Features in Mantle Cell Lymphoma: Frequency and Impact	Carla Isabel Borre	Received

AML-1015	Antifungal Prophylaxis in APL: The Azole Dilemma During ATO Induction	Christian Farag	Received

MCL-1024	Efficacy and Safety of Sonrotoclax (BGB-11417/Beqalzi) in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis	Edith Ramos Ocola	Received

AML-1029	Transplant Outcomes and Rates of Graft-Versus-Host Disease for FLT3-ITD Acute Myeloid Leukemia by Graft Source in the Era of Post-Transplant Gilteritinib Maintenance	Joseph Mort	Received

ABCL-1030	Projections of Increasing Sex, Geographic, and Age-Based Mortality Disparities in Burkitt Tumor: A Centers for Disease Control and Prevention WONDER Database Analysis Through 2035	Muhammad Ali Lak	Received

MDS-1034	Cooperative Effects of U2AF1-S34 and BCOR Mutations in Myeloid Neoplasms	Akram Abushamma	Received

CT-1036	ESTABLISHING T-CELL ENGAGING BISPECIFIC ANTIBODIES THERAPY IN COMMUNITY PRACTICE	Daniel Stein	Received

MPN-1037	Avapritinib Treatment of Patients with Advanced Systemic Mastocytosis: 4-Year Safety, Effect on Bone and First-Line Efficacy Results of the PATHFINDER Clinical Study	Michael Deininger	Received

MPN-1041	Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects	Stephanie Moore	Received

MM-1051	Clinical investigators´ (CIs) selection of induction and maintenance therapy for patients with newly diagnosed multiple myeloma (MM) eligible and ineligible for transplant	Kevin Pang	Received

ABCL-1052	Evaluation Of Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) Associated With Bispecific Antibodies In Real-world Clinical Use: A Pharmacovigilance Study (2023–2026)	Ashleigh Herbert	Received

MPN-1053	Design Verification Testing of a Highly Sensitive Multiplex qPCR Assay That Detects the JAK2 V617F Variant Commonly Present in Myeloproliferative Neoplasms	Jamie Myers	Received

MPN-1067	Comparative Efficacy of Drug Therapies on Spleen Size and Symptom Reduction in Myelofibrosis: A Frequentist Network Meta-analysis	Muhammad Ashar Ali	Received

TCL-1069	Serum proteomics reveals an immunoproteomic profile distinguishing early-stage mycosis fungoides from atopic dermatitis	Yoni Sacknovitz	Received

CLL-1075	BTK Inhibitor Failure-Associated Richter Transformation: A Distinct Clinical and Molecular Phenotype from a Single-Center Real-World Series	Faisal Ansari	Received

MPN-1076	Hematological and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population	Stephanie Moore	Received

MPN-1082	Exposure-response analyses of hemoglobin changes during epetraborole administration to nonhuman primates predict human exposure-response relationships	Stephanie Moore	Received

HL-1084	Projections of Mortality rates in Hematologic Malignancies Among Older Adults: A Centers for Disease Control and Prevention WONDER Database Analysis Through 2035	Muhammad Ali Lak	Received

AML-1085	Validation of an FLT3 Activity Signature to Predict FLT3 Inhibitor Response in Acute Myeloid Leukemia	Andrea Palasciano	Received

MM-1088	T-Cell Exhaustion–Based Transcriptomic Signature Predicts Multiple Myeloma Survival and Reveals Montelukast as an Immunomodulatory Repositioning Candidate	Ali Turunc	Received

MM-1092	Trial in progress: QUINTESSENTIAL-2: a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide	Ashley Daset	Received

MDS-1093	Clinical Efficacy of the Novel Oral NEK7 Inflammasome Inhibitor Ofirnoflast in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndromes(LR-MDS) with High-Risk Mutational Profiles: A Case Series	Devan Bursey	Received

CT-1095	beyond crs: systematic review of immune effector cell-associated hemophagocytic syndrome after CAR-t therapy	Ahmad Iftikhar	Received

MM-1098	Racial and Ethnic Disparities in Radiation Therapy Utilization Among Patients With Multiple Myeloma and Bone Metastasis: A Real-World Analysis Using TriNetX	Juhi Ardeshna-Chovatiya	Received

MPN-1106	Hematological Profile in Nonhuman Primates of Epetraborole, a Novel Boron-Containing Candidate for Oral Treatment of Polycythemia Vera	Stephanie Moore	Received

CLL-1118	EARLY OUTCOMES OF A MULTISTAKEHOLDER TREATMENT ACCESS PROGRAM FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN ARMENIA, ETHIOPIA, AND NEPAL	Lauren Herzog	Received

MM-1119	Arlocabtagene autoleucel (arlo-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma: final analysis from the phase 1 study	William Jacobs	Received

MDS-1121	First-line luspatercept versus erythropoiesis-stimulating agents for anemia in lower-risk myelodysplastic syndromes: a real-world analysis from Florida Cancer Specialists & Research Institute	Ally Bousema	Received

ALL-1125	Improving efficacy and safety outcomes in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in morphologic remission treated with obecabtageneautoleucel(obe-cel)	Sharon Martin	Received

CLL-1140	REAL-WORLD SURVIVAL OUTCOMES WITH PIRTOBRUTINIB VS BENDAMUSTINE/ RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA: A PROPENSITY SCORE-MATCHED ANALYSIS	Laraib Jahejo	Received

MPN-1148	Evaluation of Bone Formation Marker Changes in Summit, a Trial Assessing Bezuclastinib in Adults with Non-Advanced Systemic Mastocytosis: An Exploratory Analysis	Bhavna Jois	Received

HL-1149	GEOGRAPHIC DISPARITIES IN CARDIOVASCULAR MORTALITY AMONG LYMPHOMA SURVIVORS: A POPULATION-BASED COMPETING RISK ANALYSIS USING THE SEER DATABASE, 2000–2022	Jahanzeb Akhtar	Received

AML-1153	Characterization of edema adverse events in the CADENZA study of pivekimab sunirine (PVEK) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)	Beth Stapleton	Received

MPN-1154	The Effect of Bezuclastinib on the Pathobiology of Mastocytosis: Changes in Bone Marrow Mast Cells, Tryptase, and KIT p.D816V Variant Allele Frequency From the Pivotal Summit Trial	Bhavna Jois	Received

MPN-1161	The Effect of Bezuclastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results from the Pivotal Apex Trial	Bhavna Jois	Received

CML-1166	Cardiac Safety of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Real-World Propensity-Matched Comparison of Dasatinib, Nilotinib, and Imatinib	Sandipta Banerjee	Received

AML-1177	Revumenib as Maintenance for AML Following Allogeneic Stem Cell Transplantation	Hannah Goulart	Received

MPN-1187	Efficacy and Safety of Bezuclastinib in Patients With Advanced Systemic Mastocytosis: Results From the Apex Study	Bhavna Jois	Received

MCL-1190	Therapeutic Implications of TP53 and High-Risk Genomic Alterations of Mantel Cell Lymphoma: A Systemic Review	Sunanda Chagam Reddy	Received

CLL-1196	Pirtobrutinib Following Covalent BTK Inhibitor Exposure in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Pooled Analysis	Rishi Nanda	Received

MPN-1200	Real-World Use of Pacritinib in Myelofibrosis: Results From the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Platelets =50Χ109/L at Initiation (TRIPAC)	Faizan Sattar	Received

AML-1204	Real-World Incidence of Severe Ventricular Arrhythmias in Patients with Acute Myeloid Leukemia Treated with Quizartinib: Interim Results From a Postmarketing Study	Oluwatosin Fofah	Received

MPN-1206	Discovery and Characterization of DMR-001, an Fc-Null, Half-Life Optimized Monoclonal Antibody Selectively Targeting Mutant Calreticulin	Alexandra Grassian	Received

MDS-1210	Whole Genome Sequencing of Patients with Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard Of Care Methods	Adam Hockenberry	Received

AML-1217	Ziftomenib Combined With Intensive Induction (7+3) for Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Long-Term Results From the KOMET-007 Trial	Anne Brown	Received

MM-1223	Arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted CAR T cell therapy for patients with relapsed/refractory multiple myeloma: updated phase 1 safety and efficacy results in patients with 1–3 prior regimens	Will Jacobs	Received

HL-1226	IMPACT OF ALCOHOL USE DISORDER ON IN-HOSPITAL OUTCOMES AMONG PATIENTS HOSPITALIZED WITH HODGKIN LYMPHOMA: A NATIONAL INPATIENT SAMPLE STUDY, 2016–2022	Sophio Kakabadze	Received

MM-1252	Real-World Outcomes of Talquetamab in MonumenTAL-1 Trial-Ineligible Versus Trial-Eligible Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	Juan Ramirez	Received

ABCL-1267	Safety and Efficacy of Odronextamab in Relapsed/Refractory B-Cell Lymphomas: A Living Systematic Review with Subtypes and Post–CAR-T Analysis	Abrahim Durrani	Received

MPN-1268	Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Nonadvanced Systemic Mastocytosis	Bhavna Jois	Received

CLL-1272	Hematologic Toxicity and Treatment Discontinuation With Venetoclax-Based Regimens in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Randomized Trials	Rishi Nanda	Received

AML-1273	Hematologic Malignancy Diagnosed During Pregnancy	Arya Bolla	Received

CLL-1282	Cardiovascular and Treatment Discontinuation Outcomes With Next-Generation BTK Inhibitors in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Randomized Trials	Rishi Nanda	Received

CT-1297	Therapy-Related Myeloid Neoplasms Following CAR-T Therapy: Emerging Patterns, Risk Factors, and Clinical Challenges	Safwan Muhammad	Received

AML-1299	Actinomycin D in Combination with Low-dose Cytarabine and Venetoclax in Relapsed or Refractory NPM1-mutated Acute Myeloid Leukemia	Tautvile Smalinskaite	Received

MM-1301	NGS Based Assessments of Treatment Response in Patients With Multiple Myeloma Treated With Bispecific T Cell Engagers	Beatriz Mella Soares Pessoa	Received

ALL-1317	Outcomes After TKI Discontinuation in Patients with Ph+ ALL Treated with Blinatumomab and Ponatinib	Abigail Huetteman	Received

MPN-1319	Real-World Experience With Ropeginterferon Alfa-2b in Polycythemia Vera and Essential Thrombocythemia: Practice Patterns, Tolerability, and Hematologic Response at a Single Academic Center	Katherine Feder	Received

AML-1321	Melatonin Enhances Venetoclax Sensitivity Through Modulation of Apoptotic and Resistance Pathways in Acute Myeloid Leukemia	Vahid Vahedian	Received

TCL-1326	Treatment Outcomes and Prognostic Factors in Elderly Patients with Newly Diagnosed Peripheral T-Cell Lymphoma	Omar Elghawy	Received

CT-1327	State-Resolved Regulatory Profiling Identifies Product-Specific Transcription Factor and Pathway Activity in Axi-Cel and Tisa-Cel Infusion Products	Trenton Gibson	Received

MM-1330	Prophylactic tocilizumab to reduce the risk of CRS and ICANS in patients with relapsed/refractory multiple myeloma treated with elranatamab	Corbin Wright	Received

IBCL-1332	Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab (R2) Versus R2 for elapsed or Refractory Follicular Lymphoma	Bradley D. Hunter	Received

MDS-1343	Randomized Treatments for Myelodysplastic Syndrome and Related Disorders: A Comprehensive Component Network Meta-Analysis of Randomized Controlled Trials	Emi Zerzan	Received

CML-1344	Cumulative Imatinib Exposure Is Associated With Renal but Not Skeletal Dysfunction in Chronic Phase CML	AKSHAY MIDDINTI	Received

MPN-1345	From Chronic to Blast: How Diagnostic Delay Shapes Outcomes in MLN-FGFR1	Mohammad Abu-Tineh	Received

IBCL-1346	Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab (E+R2) in EPCORE FL-1 vs Real-World Chemoimmunotherapy (CIT) in Relapsed/Refractory Follicular Lymphoma (R/R FL)	Sarah Tasker	Received

CT-1348	Cardiovascular and Survival Outcomes Among Adults With Hematologic Malignancies Receiving Anthracyclines With vs Without Dexrazoxane: A Real-World Propensity-Matched Analysis	Sandipta Banerjee	Received

AML-1354	Risk Stratification of Patients Treated for NPM1-Mutated Acute Myeloid Leukemia: A Single-Center Retrospective Study.	Mohammed Almakadi	Received

CLL-1363	Second-Generation BTK Inhibitors vs Ibrutinib in CLL: A Systematic Review of Efficacy and Safety	Christopher Cooper	Received

CML-1365	Reduced Mortality, Cytopenias, and Cardiovascular Events With Asciminib Compared With Ponatinib in Previously Treated Chronic Myeloid Leukemia: A Propensity-Matched Real-World Analysis	Layal Sharrouf	Received

CT-1369	Real-World Renal Toxicity and Survival Outcomes Following HSCT: A Propensity Score- Matched TriNetX Database Analysis of Total Body Irradiation versus Chemotherapy- Only Conditioning	Wei Ju Lin	Received

ABCL-1385	Prevalence, Mortality, and Healthcare Utilization in Hemophagocytic Lymphohistiocytosis Among Lymphoma Patients: Insights From the NIS Database	Jonathan Kutcher	Received

CT-1387	Global disparities in Access to CAR-T cell therapy for hematologic malignancies Emerging challengesin equitable cellular therapy delivery	Vaishnavi Vallurupalli	Received

ABCL-1388	Secondary Primary Malignancies Associated With CD20×CD3 Bispecific T-Cell Engaging Antibodies in Patients With B-Cell Non-Hodgkin´s Lymphoma	Carmel Awadallah	Received

CT-1397	Global Research Landscape and Emerging Hotspots in CAR-NK Cell Therapy for Hematologic Malignancies: Bibliometric Analysis (2015-2026)	Pranathi Reddy Jetti	Received

ALL-1407	B-ALL: A SYSTEMATIC REVIEW AND META-ANALYSIS	Hadeel Khaled Albaoni	Received

AML-1410	Characteristics and Clinical Outcomes of Patients With Myeloid Malignancies and Cohesin Mutations	Maria Khouri	Received

MM-1417	Real-World Comparative Survival and Hospitalization Outcomes After CAR-T Relapse in Relapsed/Refractory Multiple Myeloma: Bispecific Antibodies Versus Conventional Chemotherapy	Sumbal Aziz	Received

HL-1419	TOTAL LESION GLYCOLYSIS ON INTERIM PET/CT AS A PREDICTOR OF OUTCOMES IN CLASSIC HODGKIN LYMPHOMA WITH DEAUVILLE SCORE 4–5: A LATIN-AMERICAN RETROSPECTIVE COHORT	Andre Meireles	Received

MM-1428	Infectious Complications in Hospitalized Multiple Myeloma Patients: Type-Specific Mortality, Burden, and Resource Utilization from the 2022 National Inpatient Sample	Kriti Yadav	Received

ABCL-1434	MOLECULAR PROFILING OF CHRONIC LYMPHOPROLIFERATIVE DISEASES IN BRAZILIAN PATIENTS: A REAL-WORLD NGS PANEL EXPERIENCE	Andre Meireles	Received

CT-1436	Inpatient Outcomes of Cytokine Release Syndrome and ICANS Among CAR-T Hospitalizations in the US: 2022-2023	Ashish Nepal	Received

ABCL-1447	UNCOVERING THE GENOMIC LANDSCAPE OF LBCL IN LATIN AMERICA: REPORTS OF TWO CENTERS FROM BRAZIL AND CHILE	Andre Meireles	Received

CLL-1456	Pirtobrutinib Demonstrates Superior Relapse-Free and Overall Survival Compared with Idelalisib/Rituximab in CLL: A Propensity-Matched Real-World Analysis	Ahmed Abbasi	Received

IBCL-1459	VALIDATION OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) AND TOTAL LESION GLYCOLYSIS (TLG) AS PREDICTORS OF EARLY PROGRESSION (POD24) IN FOLLICULAR LYMPHOMA: A RETROSPECTIVE STUDY OF 100 PATIENTS IN BRAZIL	Andre Meireles	Received

AML-1475	Lower-Intensity Versus Intensive Therapy in Older Adults with Newly Diagnosed AML: A Systematic Review and Meta-Analysis	Musa Kiyani	Received

AML-1476	Differential Impact of Allogeneic Stem Cell Transplantation by TP53 Mutational Status in High-Risk Myeloid Neoplasms With Complex or Monosomal Karyotype	Paloma Resende	Received

MM-1482	Acute Kidney Injury as a Risk Stratification Tool in Multiple Myeloma: Insights From a Nationwide Analysis of Mortality and 30-Day Readmission	Rushi Shah	Received

AML-1483	Multi-Hit TET2 Inactivation Identifies a High-Risk Subgroup Assigned to Favorable or Intermediate Categories by the HARMONY Framework in NPM1-Mutated AML	Paloma Resende	Received

CLL-1489	A NORMALLY COMPOSED BUT FUNCTIONALLY SILENCED NK CELL COMPARTMENT DEFINES DOUBLE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND RATIONALIZES NK-ENGAGING THERAPIES	Richard I Lewis	Received

IBCL-1506	Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab (E) With Lenalidomide and Rituximab (R2) in Relapsed/Refractory Follicular Lymphoma (R/R FL)	Sabrina Singleton	Received

CLL-1511	Real-World Overall Survival, Richter´s Transformation, and Secondary Primary Malignancy Rates in CLL: Fixed-Duration Venetoclax-Based Therapy vs. Indefinite BTK Inhibitor Monotherapy: A TriNetX Propensity-Matched Analysis	Avi Harisingani	Received

MM-1535	Socioeconomic, Demographic, and Hospital-Level Predictors of In-Hospital Mortality in Multiple Myeloma: A 2022 National Inpatient Sample Analysis	Kriti Yadav	Received

AML-1545	Quizartinib in Combination with Cladribine, Idarubicin and Cytarabine in Acute Myeloid Leukemia	Musa Yilmaz	Received

MCL-1551	Second Primary Malignancies After Mantle Cell Lymphoma: A Population-Based SEER Analysis of Cancer-Specific and Long-Term Risk	Muhammad Sarfraz Khan	Received

CLL-1557	Cardiovascular Toxicity of Ibrutinib versus Acalabrutinib in Chronic Lymphocytic Leukemia: A Propensity Score-Matched TriNetX Database Analysis	Wei Ju Lin	Received

CLL-1558	Outcomes of Venetoclax Retreatment After Prior Frontline Venetoclax-Based Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis	Mutasim Idriss	Received

AML-1566	Fitness-Based Induction Selection and Outcomes in Adult Acute Myeloid Leukemia at a Tertiary Cancer Center in Southern California	Jerry Qi	Received

CLL-1571	Breaking BTK, Not Hearts: Cardiac Safety Review With Covalent and Noncovalent BTK Inhibitors	Avantika Dhiman	Received

ABCL-1584	Persistent Excess Risk of Second Primary Malignancies in Follicular Lymphoma Survivors: Site-Specific and Latency Based Findings from SEER, 2000–2022.	Muhammad Sarfraz Khan	Received

MM-1606	The Age-Race Paradox in Multiple Myeloma: Younger Diagnosis but Persistent Early Mortality Among Black Patients in the United States	Sai Lahari Sangaraju	Received

AML-1608	Age-Stratified Survival Trends in Acute Myeloid Leukemia Before and After Venetoclax Adoption: A Comprehensive Population-Level and Real-World Analysis	Sai Mourya Meda	Received

AML-1609	Frontline Antifungal Prophylaxis with Dose-Adjusted Venetoclax Combinations in Patients with Acute Myeloid Leukemia or High-risk Myelodysplastic Syndromes	Ana Paula Orgambide-Aguilar	Received

MM-1637	Environmental Double Burden in Multiple Myeloma: PM₂.₅ Exposure and Racial Outcome Disparities Among Non-Hispanic Black and White Patients in the United States	Sai Lahari Sangaraju	Received

MM-1644	Impact of Diabetes Mellitus on Outcomes in Multiple Myeloma Patients Receiving Bispecific Antibodies: A Real-World Analysis	Juhi Ardeshna-Chovatiya	Received

ABCL-1652	Impact of Diabetes Mellitus on Outcomes and Toxicity in Patients With Diffuse Large B-Cell Lymphoma Treated With Bispecific Antibodies: A Real-World Propensity Score-Matched Analysis	Juhi Ardeshna-Chovatiya	Received

MDS-1653	Hematological Diseases and Outcomes of Extracorporeal Membrane Oxygenation Among Adults With Hematologic Malignancies: A National ECMO Recipient Registry Analysis, 2016–2022	Mariana Marrero Castillo	Received

CML-1655	Superior 96-Weeks MMR Rates And Safety With Generic Dasatinib-50mg in Newly Diagnosed CML : Large Real-World Multicentre Study From India	Sujay Rainchwar	Received

MM-1659	Prophylactic Tocilizumab During Bispecific Antibody Step-Up Dosing in Relapsed/Refractory Multiple Myeloma: CRS Mitigation, Low-Dose Strategies, and Outpatient Feasibility	Valerin Arno Encarnacion	Received

MPN-1664	KIT D816V-SELECTIVE TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF EFFICACY AND SAFETY OUTCOMES	Syed Sibt E Haider	Received

AML-1687	A phase I/II study of gilteritinib and momelotinib in adults with relapsed or refractory FLT3-mutated acute myeloid leukemia	Leticia Campoverde	Received

ABCL-1703	Aggressive B-Cell Lymphoma Reporting After COVID-19 mRNA Vaccination: A Pharmacovigilance Signal in VAERS	Tanisha Jindal	Received

CT-1719	HEMATOPOIETIC STEM CELL TRANSPLANTATION ACTIVITY IN THE EASTERN MEDITERRANEAN REGION FROM 2018–2022: AN EASTERN MEDITERRANEAN BLOOD AND MARROW TRANSPLANTATION (EMBMT) GROUP REPORT	Ibrahim Muhsen	Received

MM-1740	Narrowing Burden, Widening Gaps: A 26-Year Population-Based Analysis of Renal Failure as Contributing Cause of Death in Multiple Myeloma, 1999–2024	FNU Bhuvan	Received

MM-1752	When Fat Fuels Plasma Cell Malignancy: Three Decades of Multiple Myeloma Mortality Attributable to High BMI Across 204 Countries, 1990–2023	Dhruvinkumar Patel	Received

MM-1831	Updated Results from Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)	Janine DiGregorio	Received

MM-1833	Elranatamab in Combination With Daratumumab and Lenalidomide in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Results From MagnetisMM-6 Part 1	Alina Florou	Received

SOHO 2026

September 9-12, 2026 Houston

Help Line

Homepage

Personal Area

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 09/09/2026 TO 09/09/2026

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions